查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1241824

肌肉萎縮性脊髓側索硬化症的全球市場

Amyotrophic Lateral Sclerosis
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

肌肉萎縮性脊髓側索硬化症的全球市場2030年將達到32億美元

在COVID-19後改變的商務環境中，2022年7億7,280萬美元的肌肉萎縮性脊髓側索硬化症的全球市場，2030年將達到32億美元的規模，在2022年到2030年間預計將以19.3％的年複合成長率增長。

美國市場估算為2億3,540萬美元，中國以年複合成長率18.4％增長

美國的肌肉萎縮性脊髓側索硬化症市場，2022年2億3,540萬美元。作為世界第2位的經濟大國的中國，在2022年到2030年間預計將以的年複合成長率成為18.4％，2030年將達到5億3,450萬美元的市場規模。作為其他的關注的地區市場，有日本和加拿大，在2022年到2030年間預計將以各種17.2％和16.5％的成長。歐洲，是德國以年複合成長率14.2％成長。

調查對像企業範例

  • AB Science SA
  • Apotex, Inc.
  • Aquestive
  • Biogen, Inc.
  • Brainstorm Cell Therapeutics Inc.
  • Cytokinetics, Inc.
  • F. Hoffmann-La Roche AG
  • Genervon Biopharmaceuticals LLC
  • Ionis Pharmaceuticals, Inc.
  • Kringle Pharma Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Neuralstem, Inc.
  • Orion Corporation
  • Orphazyme A/S
  • Sanofi SA
  • Treeway BV
  • Valeant Pharmaceuticals International, Inc.
  • ViroMed Co., Ltd.

目錄

第1章 調查手法

第2章 摘要整理

  • 市場概要
  • 主要企業
  • 市場趨勢與推動因素
  • 全球市場預測

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 全球其他地區

第4章 競爭

簡介目錄
Product Code: MCP10278

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Amyotrophic Lateral Sclerosis Market to Reach $3.2 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Amyotrophic Lateral Sclerosis estimated at US$772.8 Million in the year 2022, is projected to reach a revised size of US$3.2 Billion by 2030, growing at a CAGR of 19.3% over the period 2022-2030.

The U.S. Market is Estimated at $235.4 Million, While China is Forecast to Grow at 18.4% CAGR

The Amyotrophic Lateral Sclerosis market in the U.S. is estimated at US$235.4 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$534.5 Million by the year 2030 trailing a CAGR of 18.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.2% and 16.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 14.2% CAGR.

Select Competitors (Total 23 Featured) -

  • AB Science SA
  • Apotex, Inc.
  • Aquestive
  • Biogen, Inc.
  • Brainstorm Cell Therapeutics Inc.
  • Cytokinetics, Inc.
  • F. Hoffmann-La Roche AG
  • Genervon Biopharmaceuticals LLC
  • Ionis Pharmaceuticals, Inc.
  • Kringle Pharma Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Neuralstem, Inc.
  • Orion Corporation
  • Orphazyme A/S
  • Sanofi SA
  • Treeway BV
  • Valeant Pharmaceuticals International, Inc.
  • ViroMed Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Amyotrophic Lateral Sclerosis - Global Key Competitors Percentage Market Share in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Amyotrophic Lateral Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Amyotrophic Lateral Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Amyotrophic Lateral Sclerosis Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 5: USA Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 6: USA Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • CANADA
    • TABLE 7: Canada Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 8: Canada Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • JAPAN
    • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 9: Japan Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 10: Japan Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • CHINA
    • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 11: China Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 12: China Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • EUROPE
    • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 13: Europe Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 14: Europe Historic Review for Amyotrophic Lateral Sclerosis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 15: Europe 16-Year Perspective for Amyotrophic Lateral Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
  • FRANCE
    • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 16: France Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 17: France Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • GERMANY
    • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 18: Germany Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 19: Germany Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • ITALY
    • TABLE 20: Italy Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 21: Italy Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • UNITED KINGDOM
    • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 22: UK Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 23: UK Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • REST OF EUROPE
    • TABLE 24: Rest of Europe Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 25: Rest of Europe Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • ASIA-PACIFIC
    • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 26: Asia-Pacific Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 27: Asia-Pacific Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • REST OF WORLD
    • TABLE 28: Rest of World Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 29: Rest of World Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

IV. COMPETITION